1. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004; 350:1189–1199.
Article
2. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005; 90:1294–1301.
Article
3. Ahn DK, Kim JH, Lee JI, Kim JW. Bilateral femoral neck insufficiency fractures after use of a long-term anti-resorptive drug therapy for osteoporosis: A case report. Hip Pelvis. 2015; 27:115–119.
Article
4. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007; 89:349–353.
5. Cooper KL. Insufficiency stress fractures. Curr Probl Diagn Radiol. 1994; 23:29–68.
Article
6. Ozaki D, Shirai Y, Nakayama Y, Uesaka S. A case report of insufficiency fracture of the Fossa acetabuli in a patient with rheumatoid arthritis. J Nippon Med Sch. 2000; 67:267–270.
Article
7. Robinson SP, Hammoud S, Sculco TP. Insufficiency fracture of the acetabular medial wall. J Arthroplasty. 2007; 22:768–770.
Article
8. Nieves JW, Cosman F. Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates. Curr Osteoporos Rep. 2010; 8:34–39.
Article
9. Ott SM. Fractures after long-term alendronate therapy. J Clin Endocrinol Metab. 2001; 86:1835–1836.
Article
10. Ries MD. Review of the evolution of the cementless acetabular cup. Orthopedics. 2008; 31:12 Suppl 2. pii: orthosupersite.com/view.asp?rID=37178.